 "Intas Pharma acquires Teva's UK and Ireland assets for GBP 603 mn")
The Ahmedabad-based Intas Pharmaceuticals Ltd has acquired Teva Pharmaceuticals’ assets and operations of Actavis Generics in the UK and Ireland for British Pound 603 million (approximately Rs 5110 crores) – making it one of the largest foreign acquisitions by the Indian pharmaceutical sector. The assets of Israeli firm were acquired by Intas through its subsidiary Accord Healthcare Limited.
The divestment of certain specified Actavis Generics assets and operations in the UK and Ireland was part of an undertaking that Teva made to the European Commission in the context of the review of the acquisition of Actavis Generics by Teva earlier this year. The sale will include a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England. Teva retains a number of Actavis non-overlapping generic products plus certain specialty medicines and OTC (over-the-counter) products, which have been added to Teva’s existing operations.
“The sale has been a success for Teva in that we have satisfied the EU Commission’s sale requirements for these businesses, subject to their final approval, and agreed on a good price for the assets. With the assets that it will retain, Teva will create an even stronger operation in the UK and Ireland,” commented Siggi Olafsson, President & CEO Global Generic Medicines Teva, in a press release.
For Intas Pharmaceuticals, acquisition of Teva’s UK and Ireland assets will help it to take a big leap in European healthcare sector, one of its key overseas markets. Over the years, the company has been strengthening its presence in the continent. As part of this plan, the company acquired the hospital supply business of Spain’s Corporacion Combino Pharm, for an undisclosed amount, last year.
The Ahmedabad-based firm has marketing, out-licensing and contract manufacturing arrangements for many products shipped to Europe. In 2015, Intas received approval from the EU for filgrastim, a biosimilar injection, which helps bone marrow produce white blood cells in cancer patients undergoing chemotherapy.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%